Nancy Satzler, MD
Internal Medicine · Oklahoma City, OKNPI 1225041270
Payments from drug & device makers
Across 70 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$367
- Vifor Pharma, Inc.$278
- Amgen$235
- Otsuka America Pharmaceutical, Inc.$100
- OPKO Pharmaceuticals, LLC$93
- Daiichi Sankyo Inc.$86
- plus $175 from 4 others
What the payments were for
- Food & beverage$1,31699%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 19 | $367 |
| Vifor Pharma, Inc. | 15 | $278 |
| Amgen(2 entities) | 14 | $235 |
| Otsuka America Pharmaceutical, Inc. | 6 | $100 |
| OPKO Pharmaceuticals, LLC | 5 | $93 |
| Daiichi Sankyo Inc. | 4 | $86 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $65 |
| Abbott | 1 | $65 |
| Shire North American Group Inc | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
How this compares
$1,333 in reported general payments places this provider in the 70th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $28,469 |
| TrulicityDulaglutide | 19 | $20,373 |
| JanuviaSitagliptin Phosphate | 14 | $12,348 |
| FarxigaDapagliflozin Propanediol | 13 | $9,778 |
| JardianceEmpagliflozin | 12 | $8,694 |
| PremarinEstrogens, Conjugated | 12 | $6,911 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $6,849 |
| DuleraMometasone/Formoterol | 15 | $4,901 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $4,757 |
| Arnuity ElliptaFluticasone Furoate | 13 | $4,215 |
| Montelukast Sodium | 142 | $3,869 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $3,269 |
| Losartan Potassium | 134 | $2,258 |
| Levothyroxine Sodium | 173 | $1,901 |
| Atorvastatin Calcium | 149 | $1,490 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Oklahoma City
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Samid FarooquiOklahoma City$129K
- Minh PhanOklahoma City$77K
- Ali JafryOklahoma City$33K
- Stuart SchraderOklahoma City$29K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.